Germany · Delayed Price · Currency is EUR Barinthus Biotherapeutics Statistics
Total Valuation
FRA:2AB has a market cap or net worth of EUR 19.50 million. The enterprise value is -31.79 million.
| Market Cap | 19.50M |
| Enterprise Value | -31.79M |
Important Dates
The next estimated earnings date is Thursday, May 7, 2026.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.00% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 36.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.31 |
| P/TBV Ratio | 0.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.56 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.78 |
Financial Position
The company has a current ratio of 7.77, with a Debt / Equity ratio of 0.15.
| Current Ratio | 7.77 |
| Quick Ratio | 7.16 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.23 |
| Interest Coverage | -1,138.58 |
Financial Efficiency
Return on equity (ROE) is -65.02% and return on invested capital (ROIC) is -31.88%.
| Return on Equity (ROE) | -65.02% |
| Return on Assets (ROA) | -28.08% |
| Return on Invested Capital (ROIC) | -31.88% |
| Return on Capital Employed (ROCE) | -65.87% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -4.04M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -149,048 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.27% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -50.27% |
| 50-Day Moving Average | 0.53 |
| 200-Day Moving Average | 0.80 |
| Relative Strength Index (RSI) | 39.99 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.10 |
Income Statement
| Revenue | n/a |
| Gross Profit | -113,276 |
| Operating Income | -49.46M |
| Pretax Income | -56.75M |
| Net Income | -56.58M |
| EBITDA | -47.03M |
| EBIT | -49.46M |
| Earnings Per Share (EPS) | -1.40 |
Balance Sheet
The company has 60.01 million in cash and 9.61 million in debt, with a net cash position of 50.40 million.
| Cash & Cash Equivalents | 60.01M |
| Total Debt | 9.61M |
| Net Cash | 50.40M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 63.27M |
| Book Value Per Share | 1.55 |
| Working Capital | 57.72M |
Cash Flow
In the last 12 months, operating cash flow was -40.86 million and capital expenditures -31,513, giving a free cash flow of -40.90 million.
| Operating Cash Flow | -40.86M |
| Capital Expenditures | -31,513 |
| Depreciation & Amortization | 2.46M |
| Net Borrowing | n/a |
| Free Cash Flow | -40.90M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:2AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.00% |
| Shareholder Yield | -3.00% |
| Earnings Yield | -290.12% |
| FCF Yield | -209.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |